Viracta Non Current Liabilities Total vs Total Current Liabilities Analysis

VIRX Stock

USD 0.14 0.01 6.67%

Viracta Therapeutics financial indicator trend analysis is much more than just breaking down Viracta Therapeutics prevalent accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Viracta Therapeutics is a good investment. Please check the relationship between Viracta Therapeutics Non Current Liabilities Total and its Total Current Liabilities accounts. Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Viracta Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in metropolitan statistical area.

For more information on how to buy Viracta Stock please use our How to Invest in Viracta Therapeutics guide.

Non Current Liabilities Total vs Total Current Liabilities

Non Current Liabilities Total vs Total Current Liabilities Correlation Analysis

The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Viracta Therapeutics Non Current Liabilities Total account and Total Current Liabilities. At this time, the significance of the direction appears to have significant contrarian relationship.

The correlation between Viracta Therapeutics' Non Current Liabilities Total and Total Current Liabilities is -0.25. Overlapping area represents the amount of variation of Non Current Liabilities Total that can explain the historical movement of Total Current Liabilities in the same time period over historical financial statements of Viracta Therapeutics, assuming nothing else is changed. The correlation between historical values of Viracta Therapeutics' Non Current Liabilities Total and Total Current Liabilities is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Non Current Liabilities Total of Viracta Therapeutics are associated (or correlated) with its Total Current Liabilities. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Total Current Liabilities has no effect on the direction of Non Current Liabilities Total i.e., Viracta Therapeutics' Non Current Liabilities Total and Total Current Liabilities go up and down completely randomly.

Correlation Coefficient

-0.25

Relationship Direction	Negative
Relationship Strength	Insignificant

View All Relationships

Non Current Liabilities Total

Total Current Liabilities

Total Current Liabilities is an item on Viracta Therapeutics balance sheet that include short term debt, accounts payable, accrued salaries payable, payroll taxes payable, accrued liabilities and other debts. Total Current Liabilities of Viracta Therapeutics are important to investors because some useful performance ratios such as Current Ratio and Quick Ratio require Total Current Liabilities to be accurate. The total amount of liabilities that a company is expected to pay within one year, including debts, accounts payable, and other short-term financial obligations.

Most indicators from Viracta Therapeutics' fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Viracta Therapeutics current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Viracta Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in metropolitan statistical area.

For more information on how to buy Viracta Stock please use our How to Invest in Viracta Therapeutics guide.Sales General And Administrative To Revenue is likely to rise to 53.81 in 2024, whereas Selling General Administrative is likely to drop slightly above 13.7 M in 2024.

	2021	2022	2023	2024 (projected)
Interest Expense	491K	577K	3.7M	3.9M
Depreciation And Amortization	178K	210K	492K	324.1K

Interest Expense Depreciation And Amortization

Viracta Therapeutics fundamental ratios Correlations

	Total Assets	Short Long Term Debt Total	Other Current Liab	Total Current Liabilities	Total Stockholder Equity	Property Plant And Equipment Net	Current Deferred Revenue	Net Debt	Retained Earnings	Accounts Payable	Cash	Non Current Assets Total	Non Currrent Assets Other	Cash And Short Term Investments	Common Stock Total Equity	Common Stock Shares Outstanding	Short Term Investments	Non Current Liabilities Total	Other Current Assets	Other Stockholder Equity	Total Liab	Property Plant And Equipment Gross	Total Current Assets	Short Term Debt	Common Stock	Long Term Debt
Total Assets		0.15	0.19	-0.02	0.67	0.16	-0.06	-0.48	0.65	0.34	0.69	0.55	0.57	1.0	-0.15	0.6	0.25	0.15	0.74	-0.02	0.13	0.17	1.0	-0.2	-0.14	0.3
Short Long Term Debt Total	0.15		0.47	0.21	0.03	-0.38	0.51	0.64	0.09	-0.36	-0.35	-0.29	-0.14	0.17	-0.03	0.19	0.66	0.0	0.13	0.3	0.11	-0.34	0.18	0.23	-0.01	0.44
Other Current Liab	0.19	0.47		0.68	-0.14	-0.36	0.72	0.32	-0.02	-0.22	-0.21	-0.37	-0.14	0.22	0.11	-0.04	0.52	0.01	-0.04	0.23	0.39	-0.32	0.22	0.21	0.13	0.25
Total Current Liabilities	-0.02	0.21	0.68		-0.2	-0.23	0.25	0.41	0.0	-0.02	-0.3	-0.27	0.03	-0.01	0.18	0.34	0.34	-0.25	-0.23	0.19	0.21	-0.18	-0.01	0.82	0.2	0.63
Total Stockholder Equity	0.67	0.03	-0.14	-0.2		0.17	-0.16	-0.38	0.1	0.41	0.5	0.55	0.67	0.65	0.1	0.48	0.13	-0.54	0.77	-0.15	-0.64	0.29	0.66	-0.18	0.16	0.14
Property Plant And Equipment Net	0.16	-0.38	-0.36	-0.23	0.17		-0.07	-0.22	0.49	0.14	0.12	0.8	-0.14	0.11	-0.27	0.0	-0.06	0.07	0.19	-0.93	-0.06	0.98	0.12	-0.2	-0.27	0.0
Current Deferred Revenue	-0.06	0.51	0.72	0.25	-0.16	-0.07		0.43	-0.1	-0.53	-0.36	-0.32	-0.52	-0.04	0.09	-0.47	0.4	0.01	-0.11	-0.13	0.17	-0.03	-0.04	-0.11	0.1	-0.1
Net Debt	-0.48	0.64	0.32	0.41	-0.38	-0.22	0.43		-0.33	-0.49	-0.92	-0.5	-0.45	-0.47	0.09	-0.13	0.64	-0.19	-0.32	0.05	0.0	-0.17	-0.47	0.47	0.12	0.45
Retained Earnings	0.65	0.09	-0.02	0.0	0.1	0.49	-0.1	-0.33		0.28	0.51	0.62	0.19	0.63	-0.47	0.5	0.03	0.54	0.32	-0.29	0.51	0.39	0.63	-0.01	-0.51	0.36
Accounts Payable	0.34	-0.36	-0.22	-0.02	0.41	0.14	-0.53	-0.49	0.28		0.45	0.4	0.8	0.33	-0.08	0.43	-0.22	-0.2	0.23	-0.09	-0.21	0.15	0.32	0.03	-0.07	0.25
Cash	0.69	-0.35	-0.21	-0.3	0.5	0.12	-0.36	-0.92	0.51	0.45		0.5	0.56	0.69	-0.13	0.38	-0.51	0.2	0.47	0.1	0.05	0.08	0.68	-0.33	-0.15	-0.22
Non Current Assets Total	0.55	-0.29	-0.37	-0.27	0.55	0.8	-0.32	-0.5	0.62	0.4	0.5		0.32	0.5	-0.36	0.42	-0.09	-0.02	0.55	-0.68	-0.17	0.81	0.51	-0.19	-0.34	0.12
Non Currrent Assets Other	0.57	-0.14	-0.14	0.03	0.67	-0.14	-0.52	-0.45	0.19	0.8	0.56	0.32		0.57	-0.07	0.63	-0.09	-0.31	0.41	0.2	-0.32	-0.09	0.57	0.09	-0.04	0.33
Cash And Short Term Investments	1.0	0.17	0.22	-0.01	0.65	0.11	-0.04	-0.47	0.63	0.33	0.69	0.5	0.57		-0.13	0.59	0.25	0.17	0.71	0.02	0.16	0.12	1.0	-0.2	-0.12	0.29
Common Stock Total Equity	-0.15	-0.03	0.11	0.18	0.1	-0.27	0.09	0.09	-0.47	-0.08	-0.13	-0.36	-0.07	-0.13		-0.09	-0.02	-0.38	-0.06	0.3	-0.29	-0.21	-0.13	0.18	1.0	-0.04
Common Stock Shares Outstanding	0.6	0.19	-0.04	0.34	0.48	0.0	-0.47	-0.13	0.5	0.43	0.38	0.42	0.63	0.59	-0.09		0.2	-0.17	0.53	0.17	-0.06	0.03	0.6	0.5	-0.08	0.76
Short Term Investments	0.25	0.66	0.52	0.34	0.13	-0.06	0.4	0.64	0.03	-0.22	-0.51	-0.09	-0.09	0.25	-0.02	0.2		-0.09	0.28	-0.09	0.09	0.02	0.26	0.15	0.02	0.59
Non Current Liabilities Total	0.15	0.0	0.01	-0.25	-0.54	0.07	0.01	-0.19	0.54	-0.2	0.2	-0.02	-0.31	0.17	-0.38	-0.17	-0.09		-0.15	0.07	0.89	-0.1	0.15	-0.36	-0.46	-0.18
Other Current Assets	0.74	0.13	-0.04	-0.23	0.77	0.19	-0.11	-0.32	0.32	0.23	0.47	0.55	0.41	0.71	-0.06	0.53	0.28	-0.15		-0.12	-0.27	0.26	0.73	-0.31	-0.02	0.2
Other Stockholder Equity	-0.02	0.3	0.23	0.19	-0.15	-0.93	-0.13	0.05	-0.29	-0.09	0.1	-0.68	0.2	0.02	0.3	0.17	-0.09	0.07	-0.12		0.16	-0.95	0.01	0.24	0.28	0.03
Total Liab	0.13	0.11	0.39	0.21	-0.64	-0.06	0.17	0.0	0.51	-0.21	0.05	-0.17	-0.32	0.16	-0.29	-0.06	0.09	0.89	-0.27	0.16		-0.21	0.15	-0.02	-0.35	0.07
Property Plant And Equipment Gross	0.17	-0.34	-0.32	-0.18	0.29	0.98	-0.03	-0.17	0.39	0.15	0.08	0.81	-0.09	0.12	-0.21	0.03	0.02	-0.1	0.26	-0.95	-0.21		0.13	-0.16	-0.2	0.05
Total Current Assets	1.0	0.18	0.22	-0.01	0.66	0.12	-0.04	-0.47	0.63	0.32	0.68	0.51	0.57	1.0	-0.13	0.6	0.26	0.15	0.73	0.01	0.15	0.13		-0.2	-0.12	0.3
Short Term Debt	-0.2	0.23	0.21	0.82	-0.18	-0.2	-0.11	0.47	-0.01	0.03	-0.33	-0.19	0.09	-0.2	0.18	0.5	0.15	-0.36	-0.31	0.24	-0.02	-0.16	-0.2		0.19	0.69
Common Stock	-0.14	-0.01	0.13	0.2	0.16	-0.27	0.1	0.12	-0.51	-0.07	-0.15	-0.34	-0.04	-0.12	1.0	-0.08	0.02	-0.46	-0.02	0.28	-0.35	-0.2	-0.12	0.19		-0.02
Long Term Debt	0.3	0.44	0.25	0.63	0.14	0.0	-0.1	0.45	0.36	0.25	-0.22	0.12	0.33	0.29	-0.04	0.76	0.59	-0.18	0.2	0.03	0.07	0.05	0.3	0.69	-0.02

Click cells to compare fundamentals

Viracta Therapeutics Account Relationship Matchups

Viracta Therapeutics fundamental ratios Accounts

	2019	2020	2021	2022	2023	2024 (projected)
Total Assets	37.2M	48.3M	108.6M	96.0M	56.7M	54.4M
Short Long Term Debt Total	6.3M	6.2M	5.5M	25.2M	25.6M	14.3M
Other Current Liab	2.5M	3.4M	5.4M	6.9M	10.1M	5.5M
Total Current Liabilities	9.4M	6.3M	9.1M	10.0M	38.4M	40.3M
Total Stockholder Equity	27.5M	(46.2M)	94.4M	61.1M	18.3M	19.5M
Property Plant And Equipment Net	820K	1.0M	882K	414K	464K	749.7K
Net Debt	(12.0M)	(40.9M)	(98.1M)	(11.6M)	13.2M	13.9M
Retained Earnings	(682.8M)	(50.9M)	(165.7M)	(214.9M)	(265.9M)	(279.2M)
Accounts Payable	791K	1.6M	2.9M	2.5M	2.4M	1.7M
Cash	18.3M	47.1M	103.6M	36.8M	12.3M	24.1M
Non Current Assets Total	918.0K	1.1M	3.3M	2.2M	1.7M	1.1M
Non Currrent Assets Other	98.0K	76K	2.4M	1.8M	1.3M	1.3M
Cash And Short Term Investments	34.6M	47.1M	103.6M	91.0M	53.7M	51.5M
Common Stock Shares Outstanding	2.5M	92.8K	31.9M	37.8M	38.6M	40.6M
Liabilities And Stockholders Equity	37.2M	48.3M	108.6M	96.0M	56.7M	54.4M
Non Current Liabilities Total	8K	281.0K	88.2M	5.1M	24.9M	0.0
Other Current Assets	1.7M	220K	3.4M	4.5M	857K	1.6M
Other Stockholder Equity	698.6M	4.7M	254.6M	270.7M	278.8M	292.7M
Total Liab	9.7M	94.5M	14.2M	34.9M	38.4M	27.6M
Property Plant And Equipment Gross	820K	273K	882K	414K	464K	717.8K
Total Current Assets	36.3M	47.2M	105.3M	93.7M	55.0M	52.9M
Accumulated Other Comprehensive Income	1K	(5.5M)	0.0	(178K)	9K	9.5K
Short Term Debt	6.0M	1.4M	762K	556K	25.8M	27.1M
Common Stock	3K	4K	11K	1K	4.6K	4.9K
Capital Surpluse	698.6M	718.8M	254.6M	270.7M	243.6M	436.4M
Property Plant Equipment	117.1K	1.0M	242K	148K	170.2K	245.8K
Other Assets	1.0	76.4K	0.0	1.8M	2.1M	2.2M
Net Tangible Assets	(28.4M)	(46.2M)	89.2M	55.7M	64.0M	67.2M

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

TITAN	Titan Company Limited
U	Unity Software
PAYC	Paycom Soft

Additional Tools for Viracta Stock Analysis

When running Viracta Therapeutics' price analysis, check to measure Viracta Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Viracta Therapeutics is operating at the current time. Most of Viracta Therapeutics' value examination focuses on studying past and present price action to predict the probability of Viracta Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Viracta Therapeutics' price. Additionally, you may evaluate how the addition of Viracta Therapeutics to your portfolios can decrease your overall portfolio volatility.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

Viracta Non Current Liabilities Total vs Total Current Liabilities Analysis

Non Current Liabilities Total vs Total Current Liabilities

Non Current Liabilities Total vs Total Current Liabilities Correlation Analysis

Correlation Coefficient

Non Current Liabilities Total

Total Current Liabilities

Viracta Therapeutics fundamental ratios Correlations

Viracta Therapeutics Account Relationship Matchups

High Positive Relationship

High Negative Relationship

Viracta Therapeutics fundamental ratios Accounts

Also Currently Popular

Additional Tools for Viracta Stock Analysis

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Cash And Short Term Investments	+ 1.0	Total Assets
Total Current Assets	+ 1.0	Total Assets
Total Current Assets	+ 1.0	Cash And Short Term Investments
Common Stock	+ 1.0	Common Stock Total Equity
Property Plant And Equipment Gross	+ 0.98	Property Plant And Equipment Net
Total Liab	+ 0.89	Non Current Liabilities Total

Property Plant And Equipment Gross	- 0.95	Other Stockholder Equity
Other Stockholder Equity	- 0.93	Property Plant And Equipment Net
Cash	- 0.92	Net Debt
Other Stockholder Equity	- 0.68	Non Current Assets Total
Total Liab	- 0.64	Total Stockholder Equity
Non Current Liabilities Total	- 0.54	Total Stockholder Equity